A method to further scale up large-scale production of oncolytic H-1 protoparvovirus (H-1PV) using a carrier-based production process in combination with an optimized cell culture medium

An optimized cell culture medium and process with reduced FBS, non-simultaneous seeding, and environmentally friendly lysis buffer enhance H-1PV production, achieving high yields and cost-effectiveness.

JP2025500109APending Publication Date: 2025-01-09DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024518997
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2022-09-28
Publication Date
2025-01-09

AI Technical Summary

Technical Problem

Current methods for producing oncolytic protoparvovirus H-1 (H-1PV) do not achieve high viral yields while simultaneously lowering production costs and avoiding undesirable products of animal origin.

Method used

The method involves using an optimized cell culture medium (VP-SFM™) supplemented with reduced or no fetal bovine serum (FBS), a non-simultaneous seeding and infection process, and a three-step medium exchange strategy, along with suitable microcarriers or macrocarriers for cell culture, and an environmentally friendly lysis buffer containing Tris and MgCl2 with TrypLE™ enzyme, to enhance virus production.

Benefits of technology

This approach achieves high virus yields with reduced FBS usage, lower production costs, and fewer impurities, facilitating scalable and efficient production of H-1PV.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025500109000001_ABST
    Figure 2025500109000001_ABST
Patent Text Reader

Abstract

The present invention provides a method for large-scale parvovirus production, preferably upstream optimization of oncolytic protoparvovirus H-1 (H-1PV). The method is based on the use of micro- or macrocarriers and suspension or fixed bed, respectively, optimized cell culture medium and medium exchange strategy. In summary, with optimized cell culture medium and novel medium exchange strategy, the inventors established seeded cell density and animal serum reduction, resulting in animal serum-free harvests. The tested carriers were the most suitable for high H-1PV yields, cell growth and bead-to-bead transfer capacity, and the inventors further scaled up the process from 24-well plates to Erlenmeyer flasks, spinner flasks and iCellis Nano. In conclusion, the present invention provides a large-scale method to produce oncolytic protoparvovirus H-1 with high virus yields, while at the same time lowering production costs and avoiding undesired products of animal origin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention provides a method for the upstream optimization of large-scale parvovirus production, preferably oncolytic protoparvovirus H-1 (H-1PV). The method is based on the use of micro- or macrocarriers and suspension or fixed bed, respectively, optimized cell culture medium and novel medium exchange strategy. In summary, with the optimized cell culture medium and novel medium exchange strategy, the inventors established a seeded cell density and a reduction of animal serum, resulting in an animal serum-free harvest. The tested carriers were the most suitable for high H-1PV yields, cell growth and bead-to-bead transfer capacity, and the inventors further tested the production in Erlenmeyer flasks, spinner flasks and iCellis Nano. In conclusion, the present invention provides a large-scale method for producing oncolytic protoparvovirus H-1 with high virus yields, while at the same time lowering production costs and avoiding undesired products of animal origin. [Background technology]

[0002] According to the World Health Organization (WHO), cancer was the second leading cause of death worldwide in 2018, resulting in an estimated 9.6 million deaths. Economic losses associated with cancer are significant and growing, totaling approximately $1.16 trillion in 2010 alone (Stewart 2014). Viral (OV) therapy is a promising approach to treat the disease. OVs are genetically modified or naturally occurring viruses that selectively destroy cancer cells without harming healthy tissues (Fukuhara 2016). In 2015, the first OV therapeutic (T-VEC or Imlygic™) was approved by the FDA, followed some time later by the EMA. Other OV therapeutics based on different viral platforms (https: / / webs.iiitd.edu.in / raghava / ovirustdb / clinical.php) are also in the development pipeline.

[0003] The OV drug ParvOryx® utilizes the wild-type parvovirus H-1PV, which belongs to the genus Protoparvovirus in the subfamily Parvovirinae of the family Parvoviridae (Cotmore 2014). The virus has demonstrated oncolytic and tumor-inhibitory properties during preclinical proof-of-concept studies in various cultured cell lines, animal studies (Rommelaere 2010; Nuesch 2012) and xenograft models for several human tumor types (Geletneky 2010; Faisst 1998; Angelova 2009b; Dupressoir 1989; Angelova 2009a). H-1PV has also demonstrated safety and immunogenic activity in phase I / IIa clinical trials (Geletneky 2012; Geletneky 2017) and phase II trials (Hajda 2021).

[0004] Thus, treatment of patients with the oncolytic protoparvovirus H-1PV has shown promising results in clinical trials against several types of cancer (Hajda 2021; Geletneky 2017). However, to prepare for the future market release of H-1PV, the culture medium and production process need to be adapted and optimized for robust, controlled, large-scale production, i.e., according to system parameters such as agitation speed, aeration, seeding cell density, time of infection, multiplicity of infection, time of harvest, harvest strategy, etc.

[0005] Thus, for example, see European Patent No. 3313987, which relates to a method for producing parvovirus particles using the producer cell line NB-324K, in which a cell culture medium containing animal components is used for large-scale virus production. To remove unwanted contaminants such as animal-derived components, an improved purification of infectious particles was introduced, which is based on two subsequent iodixanol density gradient ultracentrifugation steps, the first in PBS and the second in Ringer's. Furthermore, European Patent Application EP17771376.5 describes how a further optimized process for parvovirus production, based mainly on the animal-component-free cell culture medium VP-SFM™, allows for easier and more cost-effective production and purification of parvovirus produced by NB-324K cells.

[0006] However, none of the approaches provided a large-scale method for producing oncolytic protoparvovirus H-1 with high viral yields while simultaneously reducing production costs and avoiding undesirable products of animal origin.

[0007] Therefore, the technical problem underlying the present invention is to further optimize the large-scale production of parvoviruses.

[0008] This solution is achieved by providing the embodiments set forth in the claims. Summary of the Invention [Problem to be solved by the invention]

[0009] Treatment of patients with the oncolytic protoparvovirus H-1PV has shown promising results in clinical trials for several types of cancer (Hajda 2021; Geletneky 2017). These data represent the first results of producing H-1PV in a large-scale bioreactor system. However, this process needs to be adapted and optimized depending on system parameters such as agitation speed, aeration, seeding cell density, time of infection, multiplicity of infection, and harvest time.

[0010] First, the cell culture media mentioned above require the supplementation of animal serum as it is essential to stimulate cell growth, metabolism, and proliferation. Thus, the addition of animal serum such as fetal bovine serum (FBS) in cell culture remains common but is problematic in terms of quality, lot-to-lot reproducibility, animal welfare, supply, cost (vanderValk2018), and possible future regulatory restrictions. [Means for solving the problem]

[0011] Thus, the method of the present invention uses an optimized culture medium VP-SFM™ suitable for FBS-free parvovirus production (Liu 2017; Rourou 2007; Martinez 2020), and at least a two-step medium exchange strategy to reduce the amount of FBS required for FBS-free harvest by up to 80% with comparable virus yield. By adding medium exchange and reducing FBS in three steps, for example from 2% to 1% and to 0%, an increase in production of about 0.3 logs was achieved, compared to a reduction in FBS from 2% to 0% and then a second reduction in FBS to 0%, and the required FBS could be reduced by up to 40%. By applying at least a two-step medium exchange strategy in the experiments leading to the present invention, and preferably a three-step medium exchange strategy, a high virus production yield and fewer impurities for downstream processes could be achieved with FBS-free harvest.

[0012] Furthermore, using the method according to the invention, more specifically the asynchronous seeding and infection process, seeding densities of up to 7.9E3 cells / cm 2 to 5.0E3 cells / cm 2 while maintaining similar virus yields after adaptation to VP-SFM™. In this way, growth times could be shortened and cell production costs could be reduced since fewer resources were required for the seed train.

[0013] Furthermore, in the prior art, it is common to use microcarriers for suspension cultures or macrocarriers for fixed-bed bioreactors for large-scale H-1PV production with adherent cells such as the production cell line NB-324K. For large-scale production methods, the freeze-thaw cycles used in the past are difficult to implement, so the method of the present invention is carried out without the need for a trypsinization step and freeze-thaw cycles. Instead, the inventors have previously introduced Triton® X-100 (key component: 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol)-based chemical cell lysis. Lysis with Triton® X-100 has achieved satisfactory production yields with a variety of microcarriers and macrocarriers. However, the surfactant Triton® X-100 is currently considered to be ecotoxic by regulatory authorities (https: / / echa.europa.eu / authorisation-list). Therefore, in one embodiment of the present invention, a lysis buffer containing Tris, MgCl2 and the recombinant cell dissociation enzyme TrypLE™ with Tween® 80 was tested as an alternative lysis buffer because it is more environmentally friendly than the Triton® X-100 buffer and because Tween® 80 can be omitted from the lysis buffer recipe without adversely affecting the virus yield.

[0014] In the experiments leading to the present invention, several microcarriers and macrocarriers were tested. First, in one embodiment of the present invention, the solid microcarrier Cytodex® 1, a cross-linked dextran matrix with positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix, has been found to be well suited for large-scale production or attachment-enhanced CellBIND® (EA) microcarriers. The attachment-enhanced CellBIND® (EA) microcarriers have a negative surface charge due to oxygen-containing functional groups incorporated into the polystyrene surface. These microcarriers have shown promising inter-bead cell transfer capabilities during cell growth and virus production. To date, Cytodex® 1 has been reported for adenoviruses and retroviruses (Wu 2002), vaccinia virus (Liu 2017), and influenza virus A (Tree 2001).

[0015] An alternative embodiment of the method of the invention is represented by polypropylene and polyester nonwoven fibers (Fibra-Cel®) or nonwoven hydrophilized polyethylene terephthalate (PET) macrocarriers (iCELLis®), because their use provides good production yields in suspension cultures and these macrocarriers are also designed for fixed-bed bioreactors where higher yields can be achieved.

[0016] In summary, in the experiments leading to the present invention, the inventors optimized the cell culture medium and applied a new medium exchange strategy. Finally, the inventors established a reduction in seeding cell density and animal serum supplementation, resulting in an animal component-free harvest. Thus, the growth time and amount of impurities could be reduced, and the cost of cell production could be lowered since fewer resources were required for the seed train. Furthermore, the inventors tested the most suitable microcarriers and macrocarriers for high H-1PV yield, cell growth, and inter-bead transfer ability, and successfully scaled up the process from 24-well plates to Erlenmeyer flasks and spinner flasks, and in large stirred tank bioreactors or fixed-bed bioreactors with microcarriers, such as the iCELLis® 500m. 2 It is believed that production in

[0017] In summary, the present invention provides a method for producing parvovirus H-1, comprising the steps of: (a) providing a producing cell line, NB-324K; (b) producing a seed train by growing NB-324K cells under appropriate conditions; (c) providing, at the time of inoculation, an animal component-free cell culture medium supplemented with 2% animal serum, and a culture vessel containing microcarriers or macrocarriers; (d) seeding the NB-324K cells of step (b) into the culture vessel of step (c); (e) expanding NB-324K cells; (f) performing a 100% medium exchange at the time of infection with animal component-free cell culture medium containing microcarriers or macrocarriers, the animal component-free cell culture medium being supplemented with 1% animal serum or no animal serum; (g) 3-8 days after infection, harvesting the NB-324K cells using a lysis buffer comprising 1-100 mM Tris, 1-10 mM MgCl2, 2.5-10% TrypLE™, pH 9-10, with or without 0.1-1% Tween® 80, agitating the lysis buffer, followed by washing with a wash buffer comprising 1-100 mM Tris, 1-10 mM MgCl2, pH 9-10, where the lysis buffer and wash buffer are pooled together; (h) clarifying the parvovirus harvest by filtration; (i) removing unencapsulated viral DNA and contaminating host cell DNA by DNase treatment; (j) performing tangential flow filtration for buffer exchange and concentration; (k) performing anion exchange chromatography to remove empty particles and most impurities; (l) performing tangential flow filtration for buffer exchange and concentration to 0-3% Visipaque and 97-100% Ringer's solution; (m) A process for producing the final product of 48% Visipaque / Ringer's solution; The method includes:

[0018] In a preferred embodiment, in step (g), the lysis buffer comprises 25 mM Tris, 5 mM MgCl 2 , 5% TrypLE™, pH 10.

[0019] In another preferred embodiment, in step (g), the washing step is performed with a buffer comprising 25 mM Tris, 5 mM MgCl2, pH 10, and step (g) results in a buffer comprising 25 mM Tris, 5 mM MgCl2, 2.5% TrypLE™ with or without 0.1-1% Tween® 80, preferably less than 0.25% Tween® 80.

[0020] In another preferred embodiment, in step (g), the treatment with lysis buffer is carried out for 1 hour at 40° C. with shaking at 70 rpm or without CO circulating in the bioreactor (w / o), and the treatment with wash buffer is carried out for 1 minute with shaking at 70 rpm or without CO circulating in the bioreactor. [Brief description of the drawings]

[0021] [Figure 1] FIG. 1 outlines the process timeline and FBS content using VP-SFM™ media. [Diagram 2] Figure 1 shows similar H-1PV-specific virus yields using 5% FBS or a two-step FBS reduction scheme, where 3.6E4 NB-324K cells / cm2 were seeded in VP-SFM™ medium supplemented with 5% or 2% FBS. After 3 days of cell growth, infection was performed at an MOI of 0.05 and a 100% medium change with 5% or 0% FBS. Cells were harvested and lysed 4 days after infection. [Diagram 3] Figure 1 shows boosting of H-1PV-specific virus yields by three-step FBS reduction using VP-SFM™, where 5E3 NB-324K cells / cm2 were seeded in 2% FBS. After 3 days of cell growth, a first 100% medium change to either 1% or 0% FBS was performed and infection at an MOI of 0.01 was performed for production phase I from days 3 to 5. Two days after infection, a second 100% medium change was performed without FBS for production phase II from days 5 to 7. Cells were harvested and lysed on day 7, 4 days after infection. [Figure 4]Figure 1 shows a comparison of Triton® X-100 process, freeze-thaw process in Virus Tris (VT) buffer, and harvesting with or without 0.25% Tween 80, 2.5% TrypLE pH 10, and 25 mM Tris, 5 mM MgCl2. NB-324K cells were seeded in 175 cm2 flasks at 5E3 cells / cm2 in VP-SFM™ with 2% FBS for 3 days, then 100% medium changed to VP-SFM™ with 0% FBS and infected at an MOI of 0.05. Four days after infection, cells were washed with 1x PBS before lysis and harvested with the different lysis methods. [Diagram 5] Microscopic observation of cell bridges between confluent and freshly loaded microcarriers. a: Attachment enhancement (10x); b: Cytodex® 1 (10x); Scale bar = 200 μm. [Figure 6a] Figure 1 shows H-1PV-specific virus yield screening using various carriers, where 4E4 NB-324K cells / cm2 were seeded in 24-well plates with a growth area of ​​10 cm2 / ml for each carrier (11.2 cm2 / ml for iC) and shaken at 100 rpm. Cells were harvested and lysed 4 days after infection. [Figure 6b] Figure 1. Screening of H-1PV-specific virus yield after bead-to-bead transfer using various carriers. 2E4 [solid] or 4E4 [hatched] NB-324K cells / cm2 were seeded in 24-well plates with 5 cm2 / ml of growth area of ​​each microcarrier and orbitally shaken at 100 rpm. After 3 days of cell growth, cells were infected at an MOI of 0.01 and doubled the growth surface and medium volume by adding new microcarriers to fresh medium, then split 1:2 to return to starting conditions of medium volume and microcarrier density. Cells were harvested and lysed 4 days post-infection. Cells were harvested and lysed 4 days post-infection. [Figure 7]Figure 1. H-1PV-specific virus yields after scale-up for the best performing microcarriers and macrocarriers. Here, 2E4 NB-324K cells / cm2 were seeded on 10 cm2 / ml growth area (a: microcarriers EA or CD1; b: macrocarriers iC or FC) in 40 ml VP-SFM™ per 125 ml Erlenmeyer flask [solid] or 100 ml VP-SFM™ per spinner flask [hatched]. Seeding consisted of 4 cycles of 1 min at 40 rpm followed by 30 min at 0 rpm for a total seeding time of 2 h. Agitation was then set to 30-100 rpm for Erlenmeyer flasks or 40 rpm for spinner flasks. After 3 days of cell growth, cells were infected at an MOI of 0.01 and 50% of the medium was replaced with fresh medium. Cells were harvested and lysed 4 days after infection. [Figure 8] Figure 1 shows H-1PV specific virus yields in iCELLis® Nano with different fixed beds and respective Tflask run controls. In separate bioreactor runs, iCELLis® Nano fixed beds (solid) and Tflask run controls (shaded) were seeded with 5E3 cells / cm2 (0.53 m2) or 9E3 cells / cm2 (4 m2). After 3 days of cell growth with VP-SFM™ cell growth medium, a first 100% medium change was made to VP-SFM™ infection medium and infection at an MOI of 0.01 was performed for production phase I from day 3 to day 5. Two days after infection, a second 100% medium change was made with FBS-free VP-SFM™ medium for production phase II from day 5 to day 7. Cells were harvested and lysed on day 7, 4 days after infection. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] The technical problem underlying the present invention is to further optimize oncolytic protoparvovirus production, preferably large-scale production of H-1PV, since none of the currently available approaches provide a large-scale method to produce H-1PV with high virus yields while simultaneously lowering production costs and avoiding undesired products of animal origin.

[0023] In order to increase virus yields while lowering production costs and avoiding unwanted products of animal origin, in the experiments leading to the present invention, the animal component-free cell culture medium VP-SFM™ supplemented with 5% FBS during seeding and infection was compared to VP-SFM™ supplemented with 2% FBS during seeding and 0% FBS during infection.

[0024] In this respect, the term "cell culture" refers to the maintenance of cells in an artificial in vitro environment. The medium of the invention can be used to culture adherent mammalian cells, i.e. cells that adhere to the culture vessel, preferably epithelial cells, such as human neonatal kidney cells (NB-324K) transformed with simian virus 40 (Tattersall 1983), representing "producer cell lines".

[0025] The terms "culture" or "growth" refer to the maintenance of cells in vitro under conditions that favor the proliferation, differentiation or continued survival of the cells in an active or quiescent state.

[0026] The term "cell culture medium" refers to a nutrient solution for culturing cells.

[0027] The term "ingredient" refers to any compound, whether of chemical or biological origin, that can be used in cell culture media to maintain or promote cell proliferation growth. The terms "constituents," "nutrients," and "ingredients" can be used interchangeably and are all meant to refer to such compounds. Typical ingredients used in cell culture media include glucose, glutamine, glutamic acid, growth factors, insulin, and proteins.

[0028] The term "animal component-free" or "serum-free" medium is a medium that does not contain animal serum. Serum-free medium is distinguished from low-serum medium and essentially serum-free medium, both of which contain serum. More specifically, the term "serum" or rather "animal serum" refers to, for example, heat-inactivated fetal bovine serum (FBS; Biowest, France).

[0029] The process of the present invention uses an "animal component-free cell culture medium" containing the components glucose, glutamine, glutamic acid, proteins (e.g., growth factors, insulin, etc.), which is capable of supporting the culture of epithelial cells, preferably NB-324K cells, in vitro for the production of H-1PV.

[0030] The medium of the present invention can be used to grow human epithelial cells, preferably NB-324K cells, to high density and / or to increase parvovirus production. In a preferred embodiment, the process of the present invention uses an animal component-free cell culture medium containing 16-22 mM glucose, 3-5 mM glutamine, 0.1-0.6 mM glutamic acid, 0.5-1.0 mM lactate, less than 0.3 mM ammonium and 3-10 mg / ml protein, which medium is capable of supporting the culture of NB-324K cells for the production of H-1PV.

[0031] Preferably, the animal component free cell culture medium contains 17-20 mM glucose, about 4 mM glutamine, about 0.15-0.5 mM glutamic acid, about 0.7 mM lactate, less than 0.2 mM ammonium and 4-8 mg / ml protein, such as supplements, epidermal growth factor and insulin.

[0032] In a particular preferred embodiment, the animal component-free cell culture medium comprises 19.14 mM glucose, 4.25 mM glutamine, 0.174 mM glutamic acid, 0.669 mM lactate, less than 0.05 mM ammonium and about 5 mg / ml protein. These proteins include EGF, insulin and proteinaceous supplements. This medium is called VP-SFM™ (Thermofisher, USA).

[0033] Thus, according to the present invention, NB-324K cells are cultured in VP-SFM™ medium. In a more specific embodiment, NB-324K cells are cultured at 37° C. in a 5% CO2 atmosphere.

[0034] In a further embodiment, the cell culture medium is supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin, and 3-5 mM L-glutamine (Thermofisher, USA). Finally, VP-SFM™ medium supplemented with 4 mM glutamine is preferred, as higher concentrations do not result in increased virus yields, thus lowering production costs (see Table 1).

[0035] [Table 1]

[0036] In the experiments leading to the present invention, NB-324K cells were cultured in VP-SFM™ medium containing 0%, 1%, 2% or 5% FBS (see Table 1), but seeded with the addition of 5% or 2% FBS for production. Similar virus yields were shown with VP-SFM™ supplemented with 5% FBS for seeding and production compared to VP-SFM™ supplemented with 2% FBS for seeding and 0% FBS for production (see Figure 2). Thus, according to the present invention, VP-SFM™ medium supplemented with 2% FBS is preferred, and the method of the present invention preferably starts with 5% FBS in the seed train. As already mentioned above, VP-SFM™ medium supplemented with 2% FBS at seeding and 0% FBS at infection is preferred compared to 5% FBS supplementation, since it results in similar virus yields and reduces the amount of FBS by up to 80% (see Figure 2). Thus, application of the methods described herein for producing H-1PV with high viral yields can reduce production costs while at the same time avoiding undesirable products of animal origin.

[0037] For viral infection in the methods of the present invention, a virus stock of wild-type H-1PV is preferably used to infect NB-324K cells, more preferably at 0.5-5×10 per cell. 2 Plaque forming units (PFU), rather than at an MOI of 0.01 or 0.05 PFU per cell (PFU / cell). According to the present invention, NB-324K cells are infected with H-1PV at the time of seeding ("simultaneous" seeding-infection) or 2-6 days, preferably 3-6 days, after initiation of cell growth of NB-324K cells ("non-simultaneous" seeding-infection).

[0038] In one particular embodiment of the invention, 2.0×10 NB-324K cells were 4 ~5.0×10 4 cells / cm 2and the time of infection (TOI) is either at the time of seeding ("simultaneous" seeding and infection) or after 2-6 days of cell growth, preferably 3-6 days after cell growth begins for NB-324K cells ("asynchronous" seeding and infection).

[0039] For simultaneous seeding and infection, the NB-324K cells of the invention are seeded into a culture vessel pre-lined with animal component-free cell culture medium supplemented with 2% animal serum (the animal component-free cell culture medium is VP-SFM™ medium). In one particular embodiment of the invention, NB-324K cells are seeded at 2.0×10 4 ~5.0×10 4 cells / cm 2 , preferably 4.0 x 10 4 cells / cm 2 In a more specific embodiment, the cells are harvested 3 to 5 days, preferably 4 days, after infection.

[0040] For non-simultaneous seeding and infection, the NB-324K cells of the invention are seeded in a culture vessel pre-lined with animal component-free cell culture medium supplemented with 2% animal serum (the animal component-free cell culture medium is VP-SFM™ medium). In a specific embodiment, we then grow the cells for 2-6 days, preferably 3-6 days ("cell growth"). After 2-6 days of cell growth, preferably 3-6 days, the animal component-free cell culture medium supplemented with 2% animal serum is completely replaced ("100% medium exchange") with fresh animal component-free cell culture medium supplemented with 0%, 1% or 2% FBS, preferably 0% or 1% FBS (the fresh animal component-free cell culture medium is VP-SFM™ medium) ("2-0-0% FBS" and "2-1-0% FBS" strategies). At the same time, the NB-324K cells are infected with a virus stock of wild-type H-1PV. In a preferred embodiment, 0.5×10 2 ~5×10 2 Cells are infected with parvovirus at an MOI of 5.0×10 PFU / cell, or preferably 0.01 or 0.05 PFU / cell. 3 ~8.0×103 cells / cm 2 , preferably 5.0 x 10 3 or 8.0×10 3 cells / cm 2 , more preferably 5.0×10 3 cells / cm 2 NB-324K cells are seeded at a cell density of 0.01% FBS at 0.01% FBS. In a preferred embodiment, the wild-type H-1PV virus stock is contained in fresh animal-component-free cell culture medium with 100% medium change. Thus, for asynchronous seeding and infection, the TOI is after 2-6 days of cell growth, preferably 3-6 days after cell growth of NB-324K cells is initiated. In a specific embodiment, another medium change to 0% FBS is performed on day 2 post-infection, and cells are harvested 3-5 days post-infection, preferably 4 days post-infection (see FIG. 1).

[0041] Comparing the simultaneous and non-simultaneous seeding and infection processes, the seeding density of 2.0 × 10 4 ~5.0×10 4 cells / cm 2 From 5.0×10 3 ~8.0×10 3 cells / cm 2 According to the present invention, the asynchronous seeding and infection process is preferred since the seeding density is reduced to 8.0×10 by adapting VP-SFM™ medium in the asynchronous seeding and infection process. 3 From 5.0×10 3 Asynchronous infection is preferred since the number of cells / cm could be reduced again to 100. In this way, cell growth is reduced, less resources are required for the seed train, and production costs are reduced.

[0042] To avoid undesired products of animal origin, we compared a two-stage FBS reduction strategy using one or two 100% medium exchanges with a three-stage FBS reduction strategy, and Figure 1 shows an overview of all medium exchange strategies: "5-5% FBS", "2-0% FBS", "2-1-0% FBS" and "2-0-0% FBS".

[0043] According to the invention, all strategies preferably start with a method for the culture or growth of NB-324K cells, which are grown in a seed train with 5% FBS and then transferred to a culture vessel pre-lined with an animal component-free cell culture medium supplemented with 2% animal serum and grown for 2-6 days, preferably 3-6 days. After 2-6 days, preferably 3-6 days of cell growth, one 100% medium change is performed. As already mentioned above, the time of infection (TOI) is either at the time of seeding or after 2-6 days, preferably 3-6 days of cell growth, i.e. not at the same time as the 100% medium change. A 100% medium change is performed with a new animal component-free cell culture medium supplemented with 0%, 1% or 2% FBS, preferably 0% or 1% FBS (the new animal component-free cell culture medium is VP-SFM™ medium) (see the "2-0-0% FBS" or "2-1-0% FBS" strategies in Figure 3). Applying the two-step process, for example, when infected with 0% FBS (2-0% FBS), the inventors detected that the virus yield was comparable to that obtained with 5% FBS supplementation (5-5% FBS) throughout the entire process (see FIG. 2). Thus, according to the present invention, the method is carried out with at least one 100% medium exchange with fresh animal component-free cell culture medium supplemented with 0% FBS.

[0044] The three-step strategy involved one 100% medium exchange with fresh animal component-free cell culture medium supplemented with 0% or 1% FBS on days 2-6, preferably days 3-6, after seeding, or rather after the initiation of cell growth, followed by another 100% medium exchange with fresh animal component-free cell culture medium without FBS on days 1-3, preferably day 2, after infection ("2-1-0%FBS" or "2-0-0%FBS"). Application of the 2-1-0%FBS in the three-step strategy resulted in approximately 0.3 log PFU / cm compared to the 2-0-0%FBS strategy. 2 (See FIG. 3), and therefore the 2-1-0% FBS strategy is preferred in the present invention. In summary, the highest virus yield was achieved by applying the 2-1-0% FBS strategy, and depletion of FBS in the manner claimed herein is feasible.

[0045] Therefore, the method of the present invention preferably uses an optimized culture medium VP-SFM™ suitable for FBS-free production, and at least a two-step medium exchange strategy to reduce the amount of FBS required for FBS-free harvesting by up to 80% with comparable virus yield. By adding a medium exchange on day 2 after infection and reducing FBS in three steps from 2% to 1% and 0%, an increase in production of about 0.3 logs was achieved, and the required FBS could be reduced by up to 40%. By applying this strategy in the experiments leading to the present invention, high virus production yields and fewer impurities for downstream processes could be achieved with FBS-free harvesting.

[0046] To simplify large-scale H-1PV production using adherent cells such as the anchorage-dependent producer cell line NB-324K, we used carriers. In a preferred embodiment, microcarriers are provided for suspension culture and macrocarriers are intended for fixed-bed bioreactors. Therefore, the term "carrier" in the present invention is used when both systems are discussed. The characterization of microcarriers and macrocarriers according to the present invention is shown in Table 2, respectively.

[0047] [Table 2]

[0048] For simultaneous seeding and infection according to the invention, the inventors prepared a culture vessel pre-plated with microcarriers or macrocarriers in animal component-free cell culture medium supplemented with 2% animal serum. The method of the invention is then carried out as described above. Thus, in very brief terms, NB-324K cells grown in a seed train with 5% FBS are added to a culture vessel pre-plated with animal component-free cell culture medium supplemented with 2% animal serum and microcarriers or macrocarriers, and a virus stock of wild-type H-1PV is used to infect the NB-324K cells, preferably at 0.5×10 2 ~5×102 According to the present invention, NB-324K cells are seeded with 2.0×10 4 ~5.0×10 4 cells / cm 2 , preferably 4.0 x 10 4 cells / cm 2 The cells are infected with the parvovirus at a cell density of 100 to 200 μg / ml, and the cells are harvested 3 to 5 days after infection, preferably 4 days after infection.

[0049] For simultaneous seeding and infection, we added approximately 8-12 cm of cells per well. 2 , preferably about 9.5 to 11.5 cm 2 , more preferably 10 cm 2 or 11.3 cm 2 We propose the addition of a carrier.

[0050] For non-simultaneous seeding and infection, we prepare a culture vessel pre-lined with micro- or macro-carriers in a preferably animal component-free cell culture medium supplemented with 2% animal serum. The method of the invention is then carried out as described above. Thus, quite simply, NB-324K cells grown in a seed train with 5% FBS are added to a culture vessel pre-lined with animal component-free cell culture medium supplemented with 2% animal serum and micro- or macro-carriers. According to the invention, we then grow the cells for 2-6 days, preferably 3-6 days ("cell growth"). After 2-6 days of cell growth, preferably 3-6 days later, the animal component-free cell culture medium supplemented with 2% animal serum is completely replaced with new animal component-free cell culture medium supplemented with 1% FBS and fresh microcarriers, preferably to double the total growth area ("100% medium change"). In another preferred embodiment, the virus stock of wild-type H-1PV is also included in fresh animal component-free cell culture medium with 100% medium change. Thus, for asynchronous seeding and infection, the time of infection (TOI) is after 2-6 days of cell growth, preferably 3-6 days after cell growth of NB-324K cells is initiated. Medium change to 0% FBS is performed 1-3 days after cell infection, preferably 2 days after cell infection. In a specific embodiment, cells are harvested 3-5 days after TOI, i.e., post-infection, preferably 4 days post-infection (see FIG. 1).

[0051] For asynchronous seeding and infection, we used approximately 4-6 cm per well. 2 , preferably 5 cm 2 It is proposed to add a carrier.

[0052] As already mentioned above, the characterization of the microcarriers and macrocarriers according to the invention is shown in Table 2, respectively. All microcarriers showed satisfactory cell growth, except for the porous Cytopore™ 1 and Cytopore™ 2. Furthermore, all microcarriers showed promising bead-to-bead transfer ability during cell growth and virus production, allowing further cell growth skipping the trypsinization step by adding fresh microcarriers.

[0053] Therefore, according to the present invention, it is preferred that non-porous microcarriers are used, as the ability of bead-to-bead transfer without trypsinization indicates good cell growth potential in a scaled-up seed train.

[0054] To find the preferred carrier, a wide range of parameters were tested, including seeding and process agitation, carrier density, cell seeding density, MOI, TOI, presence or absence of bead-to-bead transfer, cell culture volume per vessel, and medium exchange schedule (Tables 3 and 4). The results of virus production on the carriers for the preferred carrier selection are summarized in Figure 6a and b.

[0055] [Table 3]

[0056] [Table 4]

[0057] Thus, in one preferred embodiment of the invention, the microcarriers are cross-linked dextran matrices (Cytodex®1; CD1) with positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix. In another preferred embodiment of the invention, the microcarriers represent "Attachment Enhanced CellBIND®" (EA, an attachment-enhanced surface treatment that infuses oxygen onto the surface of the microcarrier). In an alternative preferred embodiment, the macrocarriers are polypropylene and polyester non-woven fibers (Fibra-Cel®; FC) or iCELLis® (iC; or iC-500m). 2 ) is a nonwoven hydrophilized polyethylene terephthalate (PET) macrocarrier.

[0058] For simultaneous and non-simultaneous seeding and infection, microcarriers CD1 and macrocarriers iC represent preferred carriers in one embodiment of the present invention. Furthermore, macrocarriers FC and iC represent alternative preferred embodiments of the present invention, since they show good production yields in suspension culture and fixed-bed bioreactors, and higher production yields are achieved in fixed-bed bioreactors.

[0059] By applying the method of the present invention, the majority of infectious viral particles are cell-associated at the time of harvest. To harvest H-1PV, freeze-thaw cell lysis in Tris-EDTA buffer (VTE) (Leuchs 2016) or Tris-HCl buffer (VT) (Leuchs 2017) was previously reported for stationary cultures. However, the freeze-thaw method is limited to large-scale production with adherent cells on carriers, so scalable cell lysis is required. Therefore, in the experiments leading to the present invention, an alternative cell lysis method was developed. In one embodiment, the present invention refers to cell lysis with a lysis buffer containing Tris, MgCl2 and recombinant cell dissociation enzyme TrypLE™ with Tween® 80, which is more environmentally friendly than Triton® X-100 and achieves similar or higher production yields. However, Tween® 80 can be omitted from the lysis buffer recipe without adversely affecting the virus yield.

[0060] According to the present invention, lysis of NB-324K cells in step (g) is performed 3-5 days after infection using a "lysis buffer" containing 1-100 mM Tris, 1-10 mM MgCl2, 2.5-10% TrypLE™, pH 9-10, with or without 0.1-1% Tween™ 80, preferably using a lysis buffer containing 25 mM Tris, 5 mM MgCl2, 5% TrypLE™ pH 10, at 40°C for 1 hour without CO2.

[0061] According to the present invention, lysis with lysis buffer in step (g) is followed by washing with a "wash buffer" containing 1-100 mM Tris, 1-10 mM MgCl2, pH 9-10, preferably a wash buffer containing 25 mM Tris, 5 mM MgCl2, pH 10, and the lysis buffer and the wash buffer are pooled together, and the lysis and wash steps, i.e., step (g) of the present invention, result in a buffer containing 1-100 mM Tris, preferably 25 mM Tris; 1-10 mM MgCl2, preferably 5 mM MgCl2; 2.5-10% TrypLE™, preferably 2.5% TrypLE™, pH 10, with or without 0.1-1% Tween® 80, preferably less than 0.25% Tween® 80.

[0062] "TrypLE™" is a reagent containing a highly purified recombinant cell dissociation enzyme that is an alternative to porcine trypsin (GIBCO, USA).

[0063] Taken together, medium optimization and a three-step medium exchange strategy as well as recovery using a lysis buffer containing Tris, MgCl2 and the recombinant cell dissociation enzyme TrypLE™ with or without Tween® 80, preferably without Tween® 80, provide a solid basis for scaling up production.

[0064] In summary, using the optimized cell culture medium VP-SFM™ and a new medium exchange strategy, we established seeded cell density and FBS reduction, resulting in FBS-free harvests, and the tested carriers are best suited for high H-1PV yields, cell proliferation, and bead-to-bead transfer capabilities. We also demonstrated viable carrier-based production and successfully scaled up the process from 24-well plates to Erlenmeyer flasks, spinner flasks, and iCellis nano.

[0065] The following examples are intended to illustrate, but not limit, the invention. Such examples are typical of those that might be used, although other methods known to those skilled in the art may alternatively be utilized. EXAMPLES

[0066] material and method Cell lines and cell culture media NB-324K human neonatal kidney cells transformed with simian virus 40 (Tattersall 1983) were cultured in VP-SFM™ medium (Thermofisher, USA) containing 5% FBS at 37° C. in a 5% CO2 atmosphere. The cell culture medium is supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin, and 4 mM L-glutamine (see Table 1).

[0067] Virus stock and infection time In-house produced and purified virus stocks of wild-type H-1PV were used to infect cells at an MOI of 0.01 or 0.05 plaque-forming units (PFU) per cell. The time of infection (TOI) was either at the time of seeding (co-infection and seeding) or days 3–6 (non-co-infection) based on Countess cell counts.

[0068] Cell culture and virus production in static culture Simultaneous seeding and infection: 3.6E4 cells / cm 2 were seeded into a T175 flask containing VP-SFM™ complete, FBS-free VP-SFM™ (see Table 1) and infected simultaneously. Cells were harvested 4 days post-infection (dpi).

[0069] Asynchronous seeding and infection: 7.9E3 cells / cm 2were seeded into T175 flasks containing VP-SFM™ complete or VP-SFM™ cell growth medium (see Table 1). After 3 days of cell growth, the medium was completely replaced with VP-SFM™ without FBS or VP-SFM™ infection medium. At the same time, cells were infected at an MOI of 0.01 or 0.05 according to the Countess cell number of the reference T175 flask. On day 2 post-infection, another 100% medium replacement with VP-SFM™ without FBS was performed for cells that had been in VP-SFM™ infection medium since day 3. On day 4 post-infection, cells were harvested by freeze-thawing.

[0070] 1. Preparation of Carriers Characterization of the microcarriers and macrocarriers (referred to as "carriers" when discussing both systems) is shown in Table 2. Microcarriers were handled and stored in bottles siliconized with Sigmacote (Sigma-Aldrich, Germany) according to the manufacturer's instructions. Noncationic microcarriers were hydrated and autoclaved in aqua ad. injectable (B. Braun, Germany) and cationic microcarriers were hydrated and autoclaved in Ca 2+ and Mg 2+ The macrocarriers were sterile as supplied and were hydrated in cell culture medium for 30 min at 37 °C prior to use.

[0071] Cell Culture and Production Systems for Carriers Screening in 24-well plates: Carrier screening experiments were performed in 24-well ultra-low attachment plates (Corning, Germany) with 1 ml of VP-SFM™ complete per well at 37°C, 5% CO2, and 100 rpm orbital agitation using a Max Q 2000 CO2Plus (ThermoFisher Scientific, USA). Static controls were treated the same as carrier samples, but in 6-well plates (9.6 cm 2 growth area) were seeded without stirring with 2 ml of cell culture medium per well.

[0072] For simultaneous seeding and infection, 10 cm 2 or 11.3 cm 2 Carriers (macrocarriers from iCELLis® cut in half) were added per well to triplicate wells. Then, 4E4 cells / cm 2 One ml of VP-SFM™ complete containing NB-324K cells, corresponding to a seeding density of 100 μg / ml, was added to each well and infected at an MOI of 0.01. Cells were harvested 4 days post-infection using Triton® X-100.

[0073] For asynchronous seeding and infection, 5 cm per well in 2 wells 2 The growth area was then added to the 2E4 or 4E4 cells / cm 2 One ml of VP-SFM™ complete containing NB-324K cells was added to each well, corresponding to a seeding density of 10 cm. On day 3, both wells per carrier were pooled and nuclei from the samples were counted. Fresh cell culture medium VP-SFM™ complete containing virus and fresh carriers was added and the total growth area was counted to 10 cm for each pool. 2 20cm from 2 Cells were infected by doubling the cell culture volume from 2 ml to 4 ml (MOI of 0.01). A pool of used and fresh carriers was then added to 5 cm per well. 2 and 1 ml of cell culture medium. Cells were harvested on day 7, 4 days after infection, using Triton® X-100.

[0074] Microcarriers in Erlenmeyer flasks: After screening, Enhanced Attachment (EA) and Cytodex® 1 (CD1) microcarriers were cultured in 10 cm Erlenmeyer flasks containing 40 ml of VP-SFM™ complete at 37 °C, 5% CO2, and orbital agitation at 60-70 rpm using a Max Q 2000 CO2Plus (ThermoFisher Scientific, USA). 2The cells were selected for upscaling experiments in 125 ml Erlenmeyer flasks with a growth area of ​​1000 cells / ml, where 2E4 cells / cm 2 and agitation was reduced to 0 rpm for 30 min or 30 rpm for 3 h to promote cell attachment. On day 3, samples were taken to determine cell density using nuclei counts for virus infection (MOI of 0.01) and virus was added during a 50% media change with fresh VP-SFM™ complete on the same day.

[0075] Virus production in Erlenmeyer flasks using macrocarriers Macrocarriers from Fibra-Cel® and iCELLis® were also tested in 125 ml Erlenmeyer flasks using similar parameters as described for microcarriers, except that orbital agitation was 30-100 rpm and agitation during seeding was either 100 rpm, or a cycle of 40 rpm for 1 min then 0 rpm for 30 min, repeated 4 times for a total seeding time of 2 h.

[0076] Virus production in spinner flasks using carriers EA and CD1 microcarriers were cultured in 250 ml spinner flasks (Integra Biosciences, Switzerland), macrocarriers from Fibra-Cel® and iCELLis® in 500 ml spinner flasks (Integra Biosciences, Switzerland), with 100 ml of VP-SFM™ complete and 10 cm 2 The culture was further scaled up at 37 °C, 5% CO2, and 15-30 rpm agitation with a growth area of ​​2E4 cells / cm2. 2and agitation was reduced to a cycle of 0 rpm for 30 min or 40 rpm for 1 min then 0 rpm for 30 min, repeated 4 times for a total seeding time of 2 h. On day 3, samples were taken to determine cell density using nuclei counts for virus infection (MOI of 0.01 or 0.05), and virus was added during a 50% media change with VP-SFM™ complete on the same day. Cells were harvested 4 days post-infection.

[0077] Virus Production in iCELLis® Nano The iCELLis® nanosystem was 2 and 4m 2 A fixed bed size of 4 m was tested. After preparing the fixed bed according to the manufacturer's instructions, the bioreactor was filled with 850 ml of VP-SFM™ cell growth medium supplemented with 2% FBS. 2 A recirculation loop was then connected supplying an additional 3150 ml of VP-SFM™ cell growth medium to the fixed bed of 5E3 cells / cm. 2 0.53m 2 in a fixed bed or 9E3 cells / cm 2 4m 2 Fixed beds were seeded and maintained at 37°C, pH 7.3, and >30-40% dissolved oxygen. After 3-6 days of cell growth, several macrocarriers were removed from the top of the fixed bed, cells were counted, and subsequently infected at an MOI of 0.01 during a 100% medium change to VP-SFM™ infection medium supplemented with 1% FBS. Two days after infection, an additional 100% medium change to VP-SFM™ without FBS medium was performed. Cells were harvested 4 days after infection.

[0078] collect For carrier cultures seeded in wells, Erlenmeyer flasks or spinner flasks, cell culture medium was removed 4 days after infection and then 0.02 ml / cm was added for cell lysis. 2 The cells were treated with 1% Triton (registered trademark) X-100, 0.1 M Tris, pH 9.5 at 37° C. for 30 minutes.

[0079] For iCELLis® nanocultures, the cell culture medium was removed 4 days after infection. The cells in the fixed bed were then rinsed with PBS and resuspended in 0.094 ml / cm with or without 0.5% Tween® 80. 2 (0.53m 2 ) or 0.014ml / cm 2 (4m 2 ) in lysis buffer 25 mM Tris, 5 mM MgCl2, 5% TrypLE™ pH 10 for 1 hour at 40° C. without CO2 and rinsed with wash buffer 25 mM Tris, 5 mM MgCl2, pH 10. The lysis and wash are pooled together to give 25 mM Tris, 5 mM MgCl2, 2.5% TrypLE™ pH 10 with or without 0.25% Tween® 80, preferably without Tween® 80.

[0080] For static cultures, cell lysis was performed via a freeze / thaw process. The medium was removed and the infected cells were washed with 1x PBS. The medium supernatant and detached cells were centrifuged at 5000xg for 5 min. The pellet was washed with PBS and diluted with 0.02ml / cm 2 The cells were resuspended in 0.05 M Tris-HCl, pH 8.7 (VT) for 30 min at 37 °C and subjected to three freeze (liquid nitrogen) and thaw (37 °C) cycles. In addition, the following steps were performed during medium optimization and FBS reduction: After centrifugation at 5000 × g for 5 min, cell debris was discarded. The cell lysate was then sonicated for 1 min at 48 W using a Sonorex Super 10P ultrasonic homogenizer (Bandelin, Germany) and treated with DNAse (50 U / ml, Sigma, Germany) for 30 min at 37 °C after addition of 5 mM MgCl2 to remove non-encapsidated viral DNA and contaminating host cell DNA.

[0081] Quantification of viral yield Virus was quantified by performing a plaque-forming assay for infectious particles (see Leuchs (2016) for a description of the method). EXAMPLES

[0082] Comparison of two-stage FBS reduction strategy with three-stage FBS reduction strategy using 100% medium exchange We then compared a two-step FBS reduction strategy using 100% medium exchange with a three-step FBS reduction strategy. See FIG. 1 for an overview of all medium exchange strategies using VP-SFM™ medium. All strategies started with 5% FBS in the seed train, followed by cell growth in 5% or 2% FBS for 3 days, with a 100% medium exchange and coinfection on day 3 after seeding. In the two-step process, 1.0E7 PFU / cm was obtained when infected with 0% FBS (2-0%). 2 The resulting virus yields were comparable with 5% FBS addition (5-5%) throughout the entire process (see Figure 2). In a three-step strategy, a 100% medium change 3 days after seeding with 2% FBS was supplemented with either 1% FBS (2-1-0%) or no FBS (2-0-0%), followed by a second 100% medium change without FBS on day 5 for both. Three independent experiments demonstrated that the 2-1-0% FBS strategy resulted in a yield of 7.7E7 PFU / cm compared to the 2-0-0% FBS strategy. 2 Up to approximately 0.3 log PFU / cm 2 It was demonstrated that the viral yield increased with the 2-1-0% FBS strategy (Figure 3). In summary, the results show that process-wide FBS depletion is feasible with the highest viral yield achieved by applying the 2-1-0% FBS strategy. However, FBS contains components required for high viral yield that cannot be provided by VP-SFM™ alone. EXAMPLES

[0083] Chemical cell lysis required for large-scale H-1PV recovery In the method of the present invention, the majority of infectious viral particles are cell-associated at the time of harvest. To harvest H-1PV, freeze-thaw cell lysis in Tris-EDTA buffer (VTE) (Leuchs 2016) or Tris-HCl buffer (VT) (Leuchs 2017) was previously reported for stationary cultures. Large-scale production with adherent cells on carriers requires scalable cell lysis. Thus, a lysis buffer containing Tris, MgCl2 and recombinant cell dissociation enzyme TrypLE™ with or without Tween® 80 was used to harvest >2.0E7 PFU / cm 2 We have developed an alternative cell lysis method that results in satisfactory virus yields of 0.01 mg / ml (see FIG. 4).

[0084] Taken together, medium optimization and a three-step medium exchange strategy using Triton® X-100 lysis or a lysis buffer containing Tris, MgCl2 and recombinant cell dissociation enzymes with or without Tween® 80 provide a solid basis for scaling up production. EXAMPLES

[0085] Screening of cell growth on microcarriers and macrocarriers at the 24-well scale allows for cell transfer between beads For large-scale production with adherent cells, microcarriers for suspension culture or macrocarriers for fixed-bed bioreactors can be used. We screened 11 different carriers for cell growth, bead-to-bead transfer ability, and virus yield. Direct cell counting on the carriers was difficult. Therefore, glucose consumption was measured as an index of growth.

[0086] Some cell lines can build individual cell bridges from confluent microcarriers to new microcarriers for continuous cell growth. This bead-to-bead transfer can facilitate seed train cell growth without trypsinization since new microcarriers only need to be added. To test the bead-to-bead transfer capability, cells were seeded onto the microcarriers and further microcarriers were added with fresh cell culture medium by splitting 1:2 on days 4 and 7. Trypan blue cell counts of microcarriers after trypsinization were performed on days 4, before the 1:2 split, and on day 10. In Figure 5, bead-to-bead transfer with cell bridges is shown using microcarriers EA and CD1. The bead-to-bead transfer capability without trypsinization suggests good cell growth capability in scaled-up seed trains using NB-324K cells. EXAMPLES

[0087] Macrocarriers from Cytodex®1 and iCELLis® show the highest H-1PV yields After characterizing cell growth on the carriers, we applied different production strategies (simultaneous infection / asynchronous seeding and infection with or without inter-bead transfer) to identify the conditions most suitable for high virus production of H-1PV.

[0088] Simultaneous infection and seeding of carriers in 24-well ultra-low attachment plates resulted in similar virus yields for most microcarriers (HII, SP, P, PP, EA, SII, CP1, CP2). The highest yields were achieved with microcarrier CD1 and macrocarrier iC, each at 3.4E7 PFU / cm. 2 and 2.0E7 PFU / cm 2 (See FIG. 6a). The macrocarrier FC was 4.2E6 PFU / cm 2 It was the lowest yield of all the varieties.

[0089] For asynchronous seeding and infection, 4E4 cells / cm 2 In addition to the density, there was a 50% reduction in 2E4 cells / cm 2 A seeding density of 1000 μg / cm was tested for higher yields. Three days after seeding, cells were infected and a 1:2 split was performed for bead-to-bead transfer, with fresh cell culture medium and microcarriers added to maintain volume and microcarrier density. Virus yields were 4E4 cells / cm. 2 The seeding density was the highest at 4E4 cells / cm, which was similar for most microcarriers compared to simultaneous seeding and infection without bead-to-bead transfer, except for the solid HII and porous CP1 and CP2 carriers (see Figure 6b). In summary, high virus production appears possible with all tested strategies, but at 4E4 cells / cm. 2 In addition, HII and porous microcarriers CP1 and CP2 only showed high yields with simultaneous infection and seeding without inter-bead transfer.

[0090] Scale-up was explored with two selected microcarriers and two macrocarriers from 24-well plate format up to 100 ml Erlenmeyer flasks and spinner flasks. Microcarrier CD1 showed the highest yield, while the surface of microcarrier EA was comparable to the yield of a 10-layer CellSTACK® chamber. Due to the limitations of small-scale testing in 24-well plates, both macrocarriers for fixed-bed bioreactors were also selected for scale-up experiments. A wide range of parameters were tested, including seeding and process agitation, carrier density, cell seeding density, MOI, TOI, presence or absence of bead-to-bead transfer, cell culture volume per vessel, and medium exchange schedule (see Tables 3 and 4). However, only the most promising parameters are shown, using 40 ml cell culture in Erlenmeyer flasks and 100 ml cell culture in spinner flasks (see Figures 7a and b).

[0091] Microcarrier CD1 delivers 4.3E7 PFU / cm in Erlenmeyer flasks. 2yield levels of 1 log were achieved with the EA microcarrier, but 1 log lower when scaled up in spinner flasks. Microcarrier EA gave lower virus yields than CD1 in all systems.

[0092] Macrocarriers iC and FC in Erlenmeyer flasks, macrocarrier density 10 cm 2 / ml, total cell surface area 400 cm 2 3.0E7PFU / cm 2 However, when scaled up to spinner flasks, the yield was reduced due to the lack of bead-to-bead transfer and the 10 cm 2 / ml, cell surface 1000cm 2 at 1.0E6 PFU / cm 2 Results with CD1 and both macrocarriers in Erlenmeyer flasks confirm that high virus yields are possible in suspension and make these carriers prime candidates for further scale-up. EXAMPLES

[0093] First production with iCELLis® Nano 3.0E7PFU / cm produced in an Erlenmeyer flask 2 Assuming a yield of 100 ml of iCELLis®, 2 With a fixed bed of 1.5E14 PFU batch yields are expected (equivalent to 15,000 doses, 1E10 PFU per dose). Therefore, virus production was tested in a scaled-down iCELLis® nano system.

[0094] For production in iCELLis® Nano benchtop bioreactors, a newly developed medium exchange strategy of 2-1-0% FBS was used. Here, 0.53 ml 2 and 4m 2 Fixed bed sizes of 3.7E6 PFU / cm were tested, respectively. 2 and 5.7E6 PFU / cm 2(See FIG. 8). The yields were comparable for both fixed beds, but were approximately one log step lower than the macrocarriers from iCELLis® in the Erlenmeyer flasks and the stationary run control.

[0095] References Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z (2009a) Oncolytic rat parvovirus h-1pv, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther 17(7):1164-72 doi:10.1038 / mt.2009.78 Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z (2009b) Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus h-1pv. Clin Cancer Res 15(2):511-9 doi:10.1158 / 1078-0432.CCR-08-1088 Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, Soderlund-Venermo M, Tattersall P, Tijssen P, Gatherer D, Davison AJ (2014) The family parvoviridae. Arch Virol 159(5):1239-47 doi:10.1007 / s00705-013-1914-1 Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J (1989) Inhibition by parvovirus h-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 49(12):3203-8 Faisst S, Guittard D, Benner A, Cesbron JY, Schlehofer JR, Rommelaere J, Dupressoir T (1998) Dose-dependent regression of hela cell-derived tumours in scid mice after parvovirus h-1 infection. Int J Cancer 75(4):584-9 doi:10.1002 / (sici)1097-0215(19980209)75:4<584::aid-ijc15>3.0.co;2-9 Fukuhara H, Ino Y, Todo T (2016) Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 107(10):1373-1379 doi:10.1111 / cas.13027 Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schoning T, Husing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Bruck W, Just A, Frehtman V, Lobhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J (2017) Oncolytic h-1 parvovirus shows safety and signs of immunogenic activity in a first phase i / iia glioblastoma trial. Mol Ther 25(12):2620-2634 doi:10.1016 / j.ymthe.2017.08.016 Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J (2012) Phase i / iia study of intratumoral / intracerebral or intravenous / intracerebral administration of parvovirus h-1 (parvoryx) in patients with progressive primary or recurrent glioblastoma multiforme: Parvoryx01 protocol. BMC Cancer 12:99 doi:10.1186 / 1471-2407-12-99 Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero YCM, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR (2010) Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus h-1 in rat models. Neuro Oncol 12(8):804-14 doi:10.1093 / neuonc / noq023 Hajda J, Leuchs B, Angelova AL, Frehtman V, Rommelaere J, Mertens M, Pilz M, Kieser M, Krebs O, Dahm M, Huber B, Engeland CE, Mavratzas A, Hohmann N, Schreiber J, Jager D, Halama N, Sedlaczek O, Gaida MM, Daniel V, Springfeld C, Ungerechts G (2021) Phase 2 trial of oncolytic h-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res doi:10.1158 / 1078-0432.CCR-21-1020 Leuchs B, Frehtman V, Riese M, Muller M, Rommelaere J (2017) A novel scalable, robust downstream process for oncolytic rat parvovirus: Isoelectric point-based elimination of empty particles. Appl Microbiol Biotechnol 101(8):3143-3152 doi:10.1007 / s00253-016-8071-x Leuchs B, Roscher M, Muller M, Kurschner K, Rommelaere J (2016) Standardized large-scale h-1pv production process with efficient quality and quantity monitoring. J Virol Methods 229:48-59 doi:10.1016 / j.jviromet.2015.11.022 Liu S, Ruban L, Wang Y, Zhou Y, Nesbeth DN (2017) Establishing elements of a synthetic biology platform for vaccinia virus production: Biobrick design, serum-free virus production and microcarrier-based cultivation of cv-1 cells. Heliyon 3(2):e00238 doi:10.1016 / j.heliyon.2017.e00238 Martinez JAA, Milian JVF, Ueti MW, Rojas-Martinez C (2020) Innovative alternatives for continuous in vitro culture of babesia bigemina in medium free of components of animal origin. Pathogens 9(5) doi:ARTN 343 10.3390 / pathogens9050343 Nuesch JP, Lacroix J, Marchini A, Rommelaere J (2012) Molecular pathways: Rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res 18(13):3516-23 doi:10.1158 / 1078-0432.CCR-11-2325 Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21(2-3):185-95 doi:10.1016 / j.cytogfr.2010.02.011 Rourou S, van der Ark A, van der Velden T, Kallel H (2007) A microcarrier cell culture process for propagating rabies virus in vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine 25(19):3879-3889 doi:10.1016 / j.vaccine.2007.01.086 Stewart B, Wild C (2014) World cancer report 2014. International Agency for Research on Cancer Tattersall P, Bratton J (1983) Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J Virol 46(3):944-55 Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus a vaccine strains. Vaccine 19(25-26):3444-50 doi:10.1016 / s0264-410x(01)00053-6 van der Valk J, Bieback K, Buta C, Cochrane B, Dirks WG, Fu J, Hickman JJ, Hohensee C, Kolar R, Liebsch M, Pistollato F, Schulz M, Thieme D, Weber T, Wiest J, Winkler S, Gstraunthaler G (2018) Fetal bovine serum (fbs): Past - present - future. ALTEX 35(1):99-118 doi:10.14573 / altex.1705101 Wu SC, Huang GYL, Liu JH (2002) Production of retrovirus and adenovirus vectors for gene therapy: A comparative study using microcarrier and stationary cell culture. Biotechnol Prog 18(3):617-622 doi:10.1021 / bp020026p

Claims

1. 1. A method for producing parvovirus H-1 (H-1PV), comprising: (a) providing a producing cell line NB-324K; (b) producing a seed train by growing the NB-324K cells under suitable conditions; (c) providing a culture vessel containing an animal component-free cell culture medium supplemented with 2% animal serum at the time of inoculation, and microcarriers or macrocarriers; (d) seeding the NB-324K cells of step (b) into the culture vessel of step (c); (e) expanding the NB-324K cells; (f) performing a 100% medium exchange at the time of infection with animal component free cell culture medium comprising microcarriers or macrocarriers, said animal component free cell culture medium being supplemented with 1% animal serum or no animal serum; (g) 3-8 days after infection, 1-100 mM Tris, 1-10 mM MgCl, with or without 0.1-1% Tween® 80 2 The NB-324K cells are harvested with a lysis buffer containing 1-100 mM Tris, 1-10 mM MgCl, 2.5-10% TrypLE™, pH 9-10, and the lysis buffer is vortexed, followed by lysis with 1-100 mM Tris, 1-10 mM MgCl 2 lysis buffer, pH 9-10, said lysis buffer and wash buffer being pooled together; (h) clarification of the parvovirus harvest by filtration; (i) removing unencapsulated viral DNA and contaminating host cell DNA by DNase treatment; (j) performing tangential flow filtration for buffer exchange and concentration; (k) performing anion exchange chromatography to remove empty particles and most impurities; (l) performing tangential flow filtration for buffer exchange and concentration to 0-3% Visipaque and 97-100% Ringer's solution; (m) forming a final product of 48% Visipaque / Ringer's solution; The method includes:

2. In step (g), the lysis buffer is 25 mM Tris, 5 mM MgCl 2 , 5% TrypLE™, pH 10, 2 2. The method of claim 1, wherein the method is free of

3. In step (g), the washing step is carried out in 25 mM Tris, 5 mM MgCl 2 , pH 10, and step (g) is carried out in a buffer containing 25 mM Tris, 5 mM MgCl 2 3. The method of claim 1 or 2, resulting in a buffer containing 2.5% TrypLE™ with or without 0.25% Tween 80.

4. 4. The method of any one of claims 1 to 3, wherein the microcarriers are cross-linked dextran matrices with positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix, such as Cytodex® 1 or attachment-enhancing CellBIND® (EA).

5. The method of any one of claims 1 to 4, wherein the macrocarrier is a polypropylene and polyester non-woven fiber (Fibra-Cel®) or a non-woven hydrophilized polyethylene terephthalate (PET) macrocarrier (iCELLis®).

6. When the NB-324K cells are seeded and infected in step (d), the 4 ~5.0 x 10 4 cells / cm 2 or 5.0×10 if infection occurs 2-6 days after cell growth in step (e). 3 ~8.0 x 10 3 cells / cm 2 The method of claim 5, wherein the cells are seeded at a seeding cell density of

7. 7. The method of any one of claims 1 to 6, wherein the animal serum is heat-inactivated fetal bovine serum (FBS).

8. 8. The method of any one of claims 1 to 7, wherein a second 100% medium change not supplemented with animal serum is performed after step (f).

9. 9. The method of claim 8, wherein the medium of the 100% medium exchange in step (f) is supplemented with 1% FBS or is not supplemented with FBS, and the medium of the second 100% medium exchange is not supplemented with FBS.

10. The method of claim 8 or 9, wherein the second 100% medium exchange is performed 1 to 3 days after infection.

11. 11. The method of any one of claims 1 to 10, wherein the animal component free cell culture medium is a viral production serum free medium (VP-SFM™) comprising 16-22 mM glucose, 3-5 mM glutamine, 0.1-0.6 mM glutamic acid, 0.5-1.0 mM lactate, less than 0.3 mM ammonium and 3-10 μg / μl protein.

12. 12. The method of claim 11, wherein the animal component-free cell culture medium is VP-SFM™ and is supplemented with 4 mM L-glutamine.

13. 13. The method of any one of claims 1 to 12, wherein the method is initiated with 5% FBS in the seed train.

14. The cell lysis is performed using Tris, MgCl, with or without Tween® 80. 2 and recombinant cell dissociation enzyme TrypLE™, pH 10.

15. 15. The method according to any one of claims 1 to 14, wherein the method is used for suspension cultures or fixed bed bioreactors.

Citation Information

Patent Citations

  • virus production process

    JP2002513583A

  • Method for mass production and purification of parvovirus

    JP2018523992A

  • Optimized method for large-scale production of parvovirus H-1 in essentially serum-free medium

    JP2019531071A

  • A scalable method for the production and purification of oncolytic rat parvovirus H-1 based on isoelectric exclusion of empty particles

    JP2019534020A